Second, RASAL2, another RASGAP in RCC, has been shown to inhibit angiogenesis both in vitro and in vivo by decreasing the expression of vascular endothelial growth factor A (VEGFA) through the p-GSK3β/c-FOS pathway. The gene discussed is RASAL2; the disease is renal cell carcinoma.